Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor.

Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys (2014) 0.81

PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys (2014) 0.79

Up-regulation of cluster of differentiation (CD) 11b expression on the surface of canine granulocytes with human granulocyte-macrophage colony-stimulating factor (GM-CSF). J Vet Med Sci (2014) 0.76

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood (2000) 9.60

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98

The Cln3-Cdc28 kinase complex of S. cerevisiae is regulated by proteolysis and phosphorylation. EMBO J (1992) 5.92

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59

All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65

Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11

Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02

Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59

Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33

Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia. Infect Immun (1982) 3.22

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18

Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03

Detection and characterization of high affinity plasma membrane receptors for human interleukin 1. J Exp Med (1985) 3.00

Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97

Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95

Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood (1997) 2.82

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (2000) 2.82

The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem (1987) 2.78

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood (1998) 2.76

The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71

The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature (1987) 2.68

B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med (1988) 2.64

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61

Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52

Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42

One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood (1999) 2.31

Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30

Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30

Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29

Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24

Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood (1998) 2.17

Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11

Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood (1996) 2.06

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood (1999) 1.99

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92

Characterization of the human B cell stimulatory factor 1 receptor. J Exp Med (1987) 1.92

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91

Characterization of the cell surface receptor for granulocyte-macrophage colony-stimulating factor. J Biol Chem (1986) 1.90

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90

Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89

Isoelectric focusing patterns of beta-lactamases in the rapidly growing mycobacteria. Tuber Lung Dis (1992) 1.89

Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood (1988) 1.86

CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood (2001) 1.83

A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83

Technique for human marrow grafting. Blood (1970) 1.83

Characterization of the high-affinity cell-surface receptor for murine B-cell-stimulating factor 1. Proc Natl Acad Sci U S A (1987) 1.83

Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81

Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80

Development and characterization of antiserum to murine granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 1.80

Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 1.79

Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77

Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler (2012) 1.74

Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72

Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation (1996) 1.72

Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med (1994) 1.71

Marrow transplantation for thalassaemia. Lancet (1982) 1.71

Similarity between the interleukin 1 receptors on a murine T-lymphoma cell line and on a murine fibroblast cell line. Proc Natl Acad Sci U S A (1986) 1.70

Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood (1998) 1.69

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69

Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood (2001) 1.66

Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood (1989) 1.66

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol (1996) 1.64

Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol (2001) 1.63

Prenatal detection of unbalanced chromosomal rearrangements by array CGH. J Med Genet (2005) 1.63

Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood (1991) 1.63

Long-term outcome after marrow transplantation for severe aplastic anemia. Blood (1998) 1.63

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood (1994) 1.62